Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals
Recruiting
N/A
Interventional Study
Lung Cancer
Lung Neoplasms
Early Lung Cancer Detection
Cancer Screening
High-Risk Populations
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 21 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 140 (estimated)
- Sponsor
- National University Hospital, Singapore · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk indivi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
High-Risk Individuals (n = 100)
* No prior history of lung cancer
* Meets one of the following high-risk definitions:
* Current or former smoker (quit within the past 15 years), aged 55-74 years, with a smoking history of ≥30 pack-years; OR
* Never-smoker aged 55-75 years w…
Contacts
No contact information available.